1 their effectiveness and cost-effectiveness in lowrisk populations is less certain. 2 This uncertainly is due in part to low-risk patients being less likely to have cardiovascular events over the short term. For instance, in the recent Justifi cation for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study 3 -a large randomized trial comparing cardiovascular outcomes in low-risk patients randomly assigned to receive either rosuvastatin or placebo -the risk of death or nonfatal myocardial infarction over three years was 2.5% in the rosuvastatin group and 3.5% in the placebo group, which represented a large relative, but small absolute, risk reduction in cardiovascular events.
Other cholesterol-lowering interventions are available, such as diet, exercise and the use of other hypolipidemic agents, but the use of statins is the only such intervention known to reduce cardiovascular risk in people with low and high blood cholesterol levels. [4] [5] [6] [7] Thus, statins are now primarily indicated for the reduction of cardiovascular risk instead of being used mainly for the management of hypercholesterolemia. 8 With this broadening indication for use, expenditures on statins have increased and rep resent about 13% of total expenditures by pro vincial formularies in Canada. 9 The absolute number of people at low cardiovascular risk who are taking statins has increased substantially over the last decade, driven by the large number of low-risk people in the general population. 10 In addition, statins that are more effective in lowering lowCost-effectiveness of the use of low-and high-potency statins in people at low cardiovascular risk density lipoprotein (LDL) cholesterol levels have become available. 3, 11 These high-potency statins (atorvastatin and rosuvastatin) are substantially more expensive than low-potency statins available as generics (pravastatin, simvastatin, fluvastatin and lovastatin), although atorvastatin has recently become available as a generic in Canada. 12 Increasing costs and concerns over the ab solute benefit of statins in people at low cardiovascular risk has raised concerns about the costeffectiveness of statins in this group.
We performed an incremental cost-utility analysis comparing low-and high-potency statins with no statins in patients at low cardiovascular risk in a Canadian setting. We used findings from our group's recent systematic review of the efficacy of statins for primary prevention in low-risk people 13 as well as observational data from a large provincial registry of patients documenting existing statin use. Our objective was to determine which strategy represents the best use of health care resources for the publicly funded health care system, and what investment would be required to fund statins.
Methods

Cost-utility analysis
The methods are described in detail in Appendix 1 (available at www.cmaj.ca /lookup /suppl /doi :10.1503/cmaj.101281/-/DC1). In brief, we performed an incremental cost-utility analysis comparing low-and high-potency statins with no statins in patients at low cardiovascular risk. We defined low cardiovascular risk as a 10-year risk of less than 20% for cardiovascular-related death or nonfatal myocardial infarction, which approximates the risk among patients without cardiovascular disease and diabetes at baseline. Treatment strategies included no statins, the use of low-potency statins (fluvastatin, lovastatin, pravastatin and simvastatin) or the use of highpotency statins (atorvastatin and rosuvastatin).
For the primary analysis, we used Markov modelling of a patient cohort at low cardiovascular risk over a lifetime horizon (Figure 1 ), discounting costs and health outcomes at 5%. 14 The model included clinical states reflective of the outcomes reported in the randomized trials included in the systematic review used for our analysis, 13 such as death from any cause, nonfatal stroke, nonfatal myocardial infarction and unstable angina necessitating hospital admission. Because adverse events or intolerance to statins can develop, or because patients may simply stop using statins, we included health states where patients stopped using statins (Figure 1 ). Model outcomes included costs (in 2010 Canadian dollars), quality-adjusted life-years (QALYs) gained and the cost per QALY gained.
Dead (risk after 3 years based on risks in systematic review 13 The model covered two periods. For the first three years (the mean duration of the clinical trials in our systematic review), the model replicated the findings from our systematic review, 13 basing the risk of cardiovascular events and death on the findings from the review for each treatment strategy ( Consistent with published guidelines, 14 we established face and internal validity of our model by comparing model outputs (a function of both input variables and model structure) for the no-statin and statin arms with reported data from the meta-analysis. 13 We investigated predictive validity of the model by comparing life expectancy estimated by the model against the mean life expectancy of similarly aged people reported by Statistics Canada. 20 We performed all analyses using Treeage Pro 2009 (Treeage Software, Inc.).
Budget impact analysis
We used data from the 2007 Canadian Community Health Survey 21 and the National Health and Nutrition Examination Survey 22 to estimate the proportion of Canadians who might fit the following criteria for low cardiovascular risk. We used various definitions ranging from very low to low risk: (a) men and women over the age of 40 without heart disease, diabetes or stroke; (b) men over 50 and women over 60 without heart disease, diabetes or stroke; and (c) men over 50 and women over 60 without heart disease, diabetes or stroke but who either had hypertension or were smokers. We used these proportions applied to the Can adian population to estimate annual drug costs assuming different usage of low-and high-potency statins.
Results
Model validity
When we compared the proportion of patients who died or experienced nonfatal myocardial infarction or nonfatal stroke in the three longest randomized trials in our systematic review [23] [24] [25] with our model outputs at five years using input data from each of these trials separately (i.e., a test of internal validity), we noted agreement for all outcomes (R 2 > 0.99). Moreover, our model predicted a mean undiscounted life expectancy of 20.5 years for patients receiving no statins, 21.0 years for patients receiving low-potency statins and 21.4 years for patients receiving high- Note: CI = confidence interval, RR = relative risk. *Data are taken from a recent systematic review; 13 "low cardiovascular risk" was defined in the systematic review as a 10-year risk of cardiovascular-related death or nonfatal myocardial infarction of less than 20%. 18 †Defined in the reference case as the development of diabetes. ‡Because few trials of low-potency statins reported the development of diabetes, we assumed the annual rate to be similar to that reported in trials of highpotency statins.
potency statins. As expected, these values were slightly lower than the mean life expectancy for Canadians of similar age reported by Statistics Canada (men 21.7 years, women 25.6 years), 20 most of whom would be at even lower cardiovascular risk than people in cluded in our model.
Cost estimates
Over a lifetime horizon, the cost of managing a patient at low cardiovascular risk was estimated to be about $10 100 without statins, $15 200 with low-potency statins and $16 400 with highpotency statins (Table 3) . Compared with no statins, the incremental gain was 0.17 QALYs with low-potency statins and 0.30 QALYs with high-potency statins. The cost per QALY gained was $21 300 with high-potency statins versus no statins. The cost per QALY gained with lowpotency statins versus no statins was less attractive than this, which suggested that the use of lowpotency statins would not be an economically attractive strategy in the reference case (Table 3) .
Sensitivity analyses
Plausible variations in utility estimates, costs or the effect of statin treatment on adverse events Note: AHS = Alberta Health Services, CI = confidence interval, NA = not applicable. *The reference case considered a simulated cohort of middle-aged patients at low cardiovascular risk. On average, simulated patients were 59 years old (mean age of participants in statin trials) and matched the definition of "low risk" used in our systematic review 13 (i.e., a 10-year risk of cardiovascular-related death or nonfatal myocardial infarction of less than 20%
18
). †In 2010 Canadian dollars. ‡Unless stated otherwise. §Includes pharmacy dispensing fee. ¶Includes patient time and travel costs ($36) and physician cost to review laboratory test results or renew statin prescription ($35). **Risk of mild or moderate stroke at baseline was 0.46 and risk of severe stroke was 0.54. 19 † †Given that only 15% of stroke survivors at one year would have severe stroke based on a Rankin score of 4-6. ‡ ‡In the reference case, the proportion of patients undergoing revascularization who had coronary artery bypass grafting (as compared with percutaneous coronary intervention) was 0.341, based on the observed data in the APPROACH database. 16 § §Based on a weighted average of costs for ongoing care of each event. ¶ ¶Defined in the reference case as the development of diabetes.
(including the risk of new diabetes) did not appreciably affect the estimated cost per QALY gained (Table 4) . Changes in the relative risk estimates of all clinical events (upper and lower 95% confidence intervals for death, nonfatal myocardial infarction, nonfatal stroke and unstable angina) led to substantial variations in the estimated cost per QALY gained: ranging from $10 500 per QALY to $109 000 per QALY with the use of high-potency statins versus no statins. In a sensitivity analysis that considered a generic price for atorvastatin and that assumed similar efficacy between atorvastatin and high-potency statins (i.e., using the relative risk for cardiovascular events and death for high-potency statins as a class), the use of generic atorvastatin was cost saving and im proved outcomes compared with the use of low-potency statins.
When we considered an alternate definition of low risk -a 10-year risk of cardiovascularrelated death or nonfatal myocardial infarction less than 10%
8 -the cost per QALY gained ($22 100) was similar to the finding from the primary analysis.
Given that the results of the JUPITER study 3 had a strong influence on the results of the metaanalysis, 13 we completed an analysis in which we excluded the relative risk estimates from the JUPITER trial. We found that low-potency statins were no longer economically unattractive (i.e., they were no longer removed by extended dominance), and their use was associated with a cost per QALY gained of $27 600 compared with no statins; use of high-potency statins (v. low-potency statins) was associated with a cost per QALY gained of $31 300.
We modelled three different scenarios that might be expected to adversely affect the costeffectiveness of statin use in low-risk people: variation in the duration of benefit from statin use, variation in the increased risk of transition to a higher cardiovascular risk status (by acquiring new vascular risk factors), and statin use in people at even lower cardiovascular risk.
As the duration of benefit associated with statin use decreased, the cost per QALY gained became less attractive (Table 4) . When the duration of benefit from statins was assumed to be only three years, the cost per QALY gained with high-potency statins versus no statins was $353 500 (Table 4 ). Both high-and low-potency statins became more economically attractive as the assumed duration of benefit increased above 10 years.
Increasing the annual risk of transitioning to a higher cardiovascular risk status (prompting statin use) led to a less attractive cost per QALY gained. However, even when the annual risk was assumed to be 10% (likely unrealistically high), the cost per QALY gained with high-potency statins compared with no statin use was $53 200.
As expected, increasing the annual cardiovascular risk (the combined risk of nonfatal myocardial infarction or cardiovascular-related death) resulted in treatment with high-potency statins (v. no statins) becoming more economically attractive. Alternatively, decreasing the annual cardiovascular risk to 0.25% resulted in the cost per QALY becoming less attractive, at $40 100 per QALY for treatment with high-potency statins (Table 4) .
Probabilistic sensitivity analyses
Probabilistic sensitivity analysis showed that the use of high-potency statins, compared with no statins, resulted in higher costs and more QALYs gained in the majority of simulations (Appendix 1, eFigure 1, available at www .cmaj .ca /lookup /suppl/doi:10.1503/cmaj.101281/-/DC1). In addition, the majority of points (94.8%) compar- ). †Over a lifetime horizon. ‡Although the use of low-potency statins is associated with better outcomes (at higher cost) compared with no statin use, this strategy was eliminated from consideration by extended dominance, because a QALY can be purchased at a lower cost with a high-potency statin.
§Compared with no statin. Note: CI = confidence interval, JUPITER = Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin, QALY = quality-adjusted life-year, RR = relative risk. *Each strategy is compared to the preceding most expensive strategy that is not removed by dominance or extended dominance. †Including the cost of managing all complications (myocardial infarction, stroke and unstable angina necessitating hospital admission) and revascularization, but excluding the cost of medications, laboratory costs, and non-health-care costs. ‡Assuming lower prices for generic atorvastatin, which might be available in Canadian provinces, assuming a usual first entry generic price and 35% lower than brand name product, and assuming that the clinical effectiveness of atorvastatin is representative of the high-potency statins as a class. §Price for generic atorvastatin per dose reported in Alberta (www.ab.bluecross.ca/dbl/publications.html), and assuming that the clinical effectiveness of atorvastatin is representative of the high-potency statins as a class. ¶Comparing high-potency statins with low-potency statins.
ing high-potency statins with no statins fell below an arbitrary willingness-to-pay threshold of $50 000 per QALY (Appendix 1, eFigure 1). At a willingness-to-pay threshold of $25 000 per QALY gained, the likelihood that high-potency statin treatment would be cost-effective, compared with the next most expensive strategy, was 54.8% (Appendix 1, eFigure 2). The likelihood increased to 72.2% at a willingness-to-pay threshold of $50 000 per QALY gained, and to 75.9% at a willingness-to-pay threshold of $100 000 per QALY gained.
Budget impact
The annual drug costs for using statins in various low-risk populations in Canada without diabetes or cardiovascular disease are shown in Appendix 1 (eTable 2). Using the most restrictive definition of low risk (men over the age of 50 and women over 60 without diabetes, heart disease or stroke but who either have hypertension or are current smokers), we would expect an additional 4.03 million people to be eligible for statin therapy if the treatment strategy involved statin use regardless of the person's LDL cholesterol level. If treatment were limited to people with an LDL cholesterol level greater than 4.5 mmol/L, the eligible population would decrease to 374 014 (Appendix 1, eTable 2). Using the most liberal definition of low risk (men and women over the age of 40 without diabetes, heart disease or stroke, regardless of the presence of hypertension or smoking status), we would expect an additional 1.1-11.6 million people to be eligible for statin therapy, depending on whether treatment was given regardless of the LDL cholesterol level or whether LDL cholesterol levels were used to target therapy (Appendix 1, eTable 2). In this unlikely scenario, expenditures on statins would increase by $9.17 billion annually in Canada.
Interpretation
We found that use of high-potency statins compared with no statins was associated with a cost per QALY gained of $21 300. In the reference case and in most of the sensitivity analyses, lowpotency statins were not considered economically attractive, since a QALY could be purchased at a lower cost with high-potency statins than with low-potency statins. In general, our base-case results were robust to plausible variation in stochastic variables, except in analyses that limited the duration of benefit from statins to less than 10 years. The cost per QALY gained of $21 300 may seem more attractive than would be expected given the relatively high number needed to treat (239 for preventing one death based on the absolute risk reduction in mortality taken from our systematic review 13 ). However, the number needed to treat was calculated from trials in which the median duration of follow-up was two years, whereas our analysis assumed that statins would continue to reduce the risk of cardiovascular events over the patient's lifetime.
Given the projected rate of growth in expenditures, the annual drug expenditure in Canada in 2009 is expected to be nearly $30.0 billion. 9 Expanding the use of statins to a low-risk population could result in a budgetary increase of $295 million to $9.2 billion annually depending on the population and the LDL cholesterol used to target therapy. Although the cost per QALY gained is within a range that may be perceived as a reasonable use of resources, the money di rected toward statin treatment will need to come from elsewhere in the government budget: either a redirection of health care resources currently being used to fund other programs and interventions, or a redirection of funds being used elsewhere in the social system.
Previous studies have shown that statins are cost-effective (and cost saving in many subgroups) in the secondary prevention of cardiovascular disease. 2, 26 Even among higher risk patients without documented vascular disease, the use of statins has been associated with a cost per QALY gained below $20 000, which is considered by many to represent good value for money in publicly funded health care sys tems. 27−29 However, whether statins are cost-effective in people at very low cardiovascular risk has been uncertain. 2, 30 Some studies have suggested that their use in such people was associated with a cost per QALY gained of less than £20 000, 2 but only under the assumption that statin use reduces the risk of stroke, which our clinical systematic review suggests. 13 In a study involving low-risk Americans, in which the benefit from statins in low-risk people was extrapolated from the impact of statins on cholesterol levels, Pletcher and colleagues noted an incremental cost of US$42 000 per QALY gained.
30
Limitations
Our analysis has limitations. We modelled lowand high-potency statins separately, al though neither metaregression nor indirect comparisons showed conclusive evidence that use of highpotency statins was clinically superior to treatment with low-potency statins. 13 However, indirect comparisons showed consistent but nonsignificant trends to reductions in mortality and cardiovascular outcomes associated with treatment with highpotency statins.
Our estimate of long-term survival for patients with cardiovascular events was taken from an observational cohort of patients who underwent catheterization, thereby excluding patients who do not undergo catheterization. However, the effect of this bias was likely minimal because our model was robust to changes in these survival estimates. Treating patients without a "disease" with a medication to reduce risk raises issues about the impact of medication use on quality of life. If future evidence suggests that statins negatively affect quality of life, this should be incorporated in future economic analyses.
Another potential limitation is that our effectiveness results included data from the recent JUPITER trial, 3 which contributed significantly to the overall reduction in risk observed with a highpotency statin strategy. Although the validity of this trial has been questioned, 4 even when we excluded the JUPITER trial from our analysis, the results were largely similar, as were the results from analyses in which we used various definitions of low cardiovascular risk. Our analysis hinges upon the assumption that statins continue to reduce the risk of cardiovascular events over the patient's lifetime. In support of this assumption, we found no suggestion that the efficacy of statins was lower in the longer term compared with the efficacy in short-term randomized studies.
Conclusion
Use of high-potency statins in patients at low cardiovascular risk was associated with a cost per QALY gained that appeared to be economically attractive by current standards, assuming that statin use would continue to effectively reduce the risk of cardiovascular events and death for at least 10 years after initial prescription. High-potency statins may be more attractive than low-potency ones, although definitive evidence of their superior efficacy is lacking. On the basis of our findings, it appears that prov inces should continue to fund the use of all statins in a similar fashion, regardless of potency, for use in patients at low cardiovascular risk. However, the overall expenditure on statins in low-risk populations would be substantial, and the ramifications of this practice should be carefully considered by policy-makers.
